|
EP3873540A4
(en)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
WO2020092839A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
EP3965829A4
(en)
|
2019-05-06 |
2023-05-24 |
Malcolm, Thomas |
ADAPTED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEM FOR CANCER TUMORS
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
US12221622B2
(en)
|
2019-05-10 |
2025-02-11 |
The Regents Of The University Of California |
Modified pluripotent cells
|
|
WO2021146222A1
(en)
*
|
2020-01-13 |
2021-07-22 |
Sana Biotechnology, Inc. |
Modification of blood type antigens
|
|
KR20220158046A
(ko)
*
|
2020-03-25 |
2022-11-29 |
사나 바이오테크놀로지, 인크. |
신경계 장애 및 병태의 치료를 위한 면역저하성 신경 세포
|
|
AU2021262766A1
(en)
*
|
2020-04-27 |
2022-11-24 |
Sana Biotechnology, Inc. |
Repeat dosing of hypoimmunogenic cells
|
|
EP4149525A4
(en)
*
|
2020-05-15 |
2024-08-28 |
Rxcell Inc. |
HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES
|
|
WO2022036150A1
(en)
|
2020-08-13 |
2022-02-17 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
JP2024501971A
(ja)
*
|
2020-12-31 |
2024-01-17 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃａｒ－ｔ活性を調節するための方法及び組成物
|
|
EP4334718A4
(en)
*
|
2021-05-06 |
2025-04-23 |
Mayo Foundation for Medical Education and Research |
ASSESSMENT AND TREATMENT OF CANCER
|
|
BR112023024231A2
(pt)
|
2021-05-19 |
2024-01-30 |
Sana Biotechnology Inc |
Células t primárias rhd negativas hipoimunogênicas
|
|
US20240226164A1
(en)
|
2021-05-27 |
2024-07-11 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
KR20240046319A
(ko)
|
2021-07-14 |
2024-04-08 |
사나 바이오테크놀로지, 인크. |
저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
|
|
MX2024000713A
(es)
*
|
2021-07-16 |
2024-03-25 |
Sana Biotechnology Inc |
Vectores policistrónicos para terapias a base de células.
|
|
WO2023008918A1
(ko)
*
|
2021-07-28 |
2023-02-02 |
의료법인 성광의료재단 |
B2m 유전자의 발현이 저해된 유전적으로 조작된 줄기세포 및 이의 이용방법
|
|
US20240358761A1
(en)
|
2021-08-11 |
2024-10-31 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
EP4384598A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
JP2024535677A
(ja)
|
2021-08-11 |
2024-10-02 |
サナ バイオテクノロジー，インコーポレイテッド |
即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
|
|
AU2022327174A1
(en)
|
2021-08-11 |
2024-02-15 |
Sana Biotechnology, Inc. |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
US20250313861A1
(en)
|
2021-10-22 |
2025-10-09 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
CN119072319A
(zh)
|
2021-12-23 |
2024-12-03 |
萨那生物技术股份有限公司 |
用于治疗自身免疫性疾病的嵌合抗原受体(car)t细胞及相关方法
|
|
KR20240142624A
(ko)
*
|
2022-01-10 |
2024-09-30 |
사나 바이오테크놀로지, 인크. |
만능줄기세포에서 분화된 면역저하 베타세포 및 관련 용도 및 방법
|
|
US20250302953A1
(en)
|
2022-02-14 |
2025-10-02 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
EP4479416A1
(en)
|
2022-02-17 |
2024-12-25 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
KR20250008812A
(ko)
*
|
2022-04-07 |
2025-01-15 |
페이트 세러퓨틱스, 인코포레이티드 |
동종 세포 치료에 사용하기 위한 면역 인식 경로에 관여하는 스텔스 전략
|
|
US20250222029A1
(en)
|
2022-04-08 |
2025-07-10 |
Fate Therapeutics, Inc. |
Chimeric antigen receptor for tumor targeting
|
|
US20250228943A1
(en)
|
2022-04-08 |
2025-07-17 |
Fate Therapeutics, Inc. |
Cells having solid tumor targeting backbone and use thereof
|
|
EP4515231A1
(en)
*
|
2022-04-28 |
2025-03-05 |
Allogene Therapeutics, Inc. |
Methods for donor cell analysis
|
|
WO2023230533A1
(en)
*
|
2022-05-25 |
2023-11-30 |
Jasper Therapeutics, Inc. |
Modified stem cell compositions and methods for use
|
|
JP2025518125A
(ja)
*
|
2022-05-25 |
2025-06-12 |
マルコルム，トーマス |
生体模倣型ナノ小胞を作製するための低免疫原性細胞
|
|
US20260002124A1
(en)
|
2022-07-01 |
2026-01-01 |
Novo Nordisk A/S |
Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
|
|
WO2024097313A1
(en)
*
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Methods for producing t cell therapy products
|
|
CN118207165B
(zh)
*
|
2022-12-07 |
2026-03-20 |
士泽生物医药（苏州）有限公司 |
一种表达stc1的通用型细胞及其制备方法
|
|
CN115612673A
(zh)
*
|
2022-12-14 |
2023-01-17 |
卡瑞济(北京)生命科技有限公司 |
一种改善car-t细胞群的持久性的方法
|
|
WO2024183750A1
(en)
*
|
2023-03-07 |
2024-09-12 |
Qihan Hong Kong Limited |
A novel immune cell and use thereof for treating diseases
|
|
EP4735585A1
(en)
|
2023-06-30 |
2026-05-06 |
Novo Nordisk A/S |
Enhancing neuronal differentiation of neural progenitor cells
|
|
WO2025029826A1
(en)
*
|
2023-07-31 |
2025-02-06 |
Seraxis, Inc. |
Modified therapeutics cells and methods relating to the same
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
WO2025096757A1
(en)
|
2023-11-01 |
2025-05-08 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas
|
|
CN117737130A
(zh)
*
|
2023-12-21 |
2024-03-22 |
南京康和细胞基因工程研究院有限公司 |
一种提高通用型car-t细胞产量和活性的制备方法
|